Genetics of Endocrine and Neuroendocrine Neoplasias–for health professionals (PDQ®)

SECTIONS

Changes to This Summary (11/12/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Multiple Endocrine Neoplasia Type 1

Revised text to state that surgery is commonly performed for most functional tumors and for nonfunctioning neuroendocrine tumors when the tumor exceeds 2 to 3 cm because the likelihood of distant metastases is high (cited Bettini et al. as reference 64).

Added Vezzosi et al. as reference 77.

Multiple Endocrine Neoplasia Type 2

Revised text to state that between 1% and 10% of individuals with apparently sporadic medullary thyroid cancer (MTC) will carry a germline RET mutation, underscoring the importance of testing all individuals diagnosed with MTC (cited Sarika et al. as reference 106).

This summary is written and maintained by the PDQ Cancer Genetics Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summaryand PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Carney-Stratakis Syndrome

Next section >
About This PDQ Summary

-.-.-.-

THYROID CANCER